Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Summer Feng

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Drug Safety|March 2, 2026
QT Prolongation Risk of Antibody-Drug ConjugatesXu Steven Xu, Kinjal Sanghavi, Summer Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2024
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancerChengcong Chen, Yan Summer Feng, Ziyi Wang, et al.
Clinical Pharmacokinetics|March 17, 2023
Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in OncologyChengcong Chen, Xiaoqing Fan, Lin Zhang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 3, 2025
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotinSummer Feng, Rudy Gunawan, Chaitali Passey, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Drug Safety|March 2, 2026
QT Prolongation Risk of Antibody-Drug ConjugatesXu Steven Xu, Kinjal Sanghavi, Summer Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2024
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancerChengcong Chen, Yan Summer Feng, Ziyi Wang, et al.
Clinical Pharmacokinetics|March 17, 2023
Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in OncologyChengcong Chen, Xiaoqing Fan, Lin Zhang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 3, 2025
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotinSummer Feng, Rudy Gunawan, Chaitali Passey, et al.
Pageof 1